Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teriparatide for osteoradionecrosis of the jaws
ChiCTR2300067899Phase 4Recruiting
- Sponsor
- Department of Oral and Maxillofacial Surgery, Affiliated Stomatology Hospital
- Start
- Jun 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of teriparatide in osteoradionecrosis of the jaws (ORN) (2 arms), sponsored by Department of Oral and Maxillofacial Surgery, Affiliated Stomatology Hospital. Primary endpoints: clinical stage at week 48, C-terminal telopeptide of type I collagen at week 48 and 3 more. Started Jun 2022; status: recruiting.
02
Drugs
teriparatide
03
Conditions
osteoradionecrosis of the jaws (ORN)
Beyond the preview
Go deeper on ChiCTR2300067899.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300067899.